Why Are Correct Screening Procedures So Important?

GVP Module VI  makes it clear that regulators expect consistent screening to be an integral part of your day-to-day drug safety operations. For each marketing authorisation you hold, you are expected to:

  • Understand which publication databases are most relevant to each medicinal product
  • Systematically monitor these for publications worldwide at least once a week
  • Systemically monitor all “active substances” for which you hold Marketing Authorisations within the EU (where not listed by the EMA)
  • Monitor articles published locally in each territory where your product is marketed
  • Route the results of this activity to the appropriate departments within your company
  • Understand and comply with the time deadlines that apply to Individual Case Safety Reports Literature Screening – even if a third party is completing your screening
  • Avoid reporting duplicate ICSRs within literature
  • Describe and analyse any “new and significant safety findings” in the medicinal product’s PSUR
  • Understand and comply with the requirement to immediately notify regulators of new safety information from screening

PrimeVigilance operates a comprehensive Worldwide Pharmacovigilance Literature Screening Service as part of the suite of drug safety services offered by the company. Features include:

  • Conduct of searches via validated databases e.g. Medline and Embase – Screening of Abstracts for identification of potential ICSRs
  • Screening of Abstracts for identification of potential new and significant safety findings for inclusion in PSURs
  • Pregnancy outcomes (including termination) with no adverse outcomes
  • Use in paediatric populations
  • Compassionate supply, named patient use
  • Lack of efficacy
  • Asymptomatic overdose, abuse or misuse
  • Medication error where no adverse events occurred
  • Important non-clinical safety results. Ordering selected full publications for evaluation of ICSRs or safety issues
Targeted Literature Screening For Safety Assessments And Benefit Risk Analysis.

The PrimeVigilance Global Literature Monitoring Team of more than 40 medical professionals and life-science experts currently screens over 750 unique INNs, and that number is constantly increasing. Our service is structured around the delivery of quality outcomes for your pharmacovigilance system and is focused on the continual review and quality check of literature references. Our process is tracked and documented at every step to ensure quality and compliance with worldwide regulations. Leveraging the PrimeVigilance Global Literature Monitoring Service delivers costs benefits through our scale of operation, and allows you to focus on other areas of your core business.

Your service may be extended to full or part service including:

  • Entry of identified cases onto a validated safety database
  • Full medical review of ICSRs
  • Regulatory reporting of ICSRs
  • Signal Detection and Benefit risk analysis
  • Medical Assessment of safety issues
Why Choose PrimeVigilance For Your Pharmacovigilance Literature Screening Service?

The requirement to proactively screen the published medical and scientific literature as part of a pharmacovigilance system can lead to difficulties: the screening can be time-consuming and resource intensive; inadequate searches are a common finding during regulatory authority inspections; and the identified cases can be complex and difficult to evaluate and to enter onto the safety database.

One benefit of contracting PrimeVigilance to carry out your Literature Screening for you is that we have been offering it as part of our range of drug safety services for a number of years. Our staff have extensive experience in this arena and can comprehensively manage your literature screening requirements in a cost-effective manner. Involving medical review of cases rather than adopting a mechanistic approach can also help to identify important signals in the literature. We can also utilise our existing international network to establish screening of the local, non-indexed medical and scientific literature.

We can also carry out literature searches for purposes of signal evaluation or for identifying safety concerns for inclusion in PSURs.

Just one of the pharmacovigilance services from PrimeVigilance

For more information contact PrimeVigilance today

Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products
Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report
21CFR314.80 Postmarketing reporting of adverse drug experiences

This site uses cookies to personalise and customise your experience. No cookies collect personal or sensitive information. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Cookie Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services